This review presents a clinically focussed introduction to cell-based immunotherapy in solid organ transplantation. The potential benefits and risks of cell-based immunotherapeutics are critically discussed.
INTRODUCTION
The concept of using regulatory cells as therapeutic agents has roots in early research in organ transplantation. Kilshaw, Brent and Pinto [1] reported in the mid-70s that whole lymphocyte preparations from mice with long-surviving skin grafts, tolerized with donor alloantigen extract and antilymphocyte serum, could significantly prolong allograft survival in a second set of mice. Over the course of the next decade, more refined experiments demonstrated that purified CD4 þ or CD8 þ T cells could prevent T effector -cell-mediated rejection of heart allografts in rodents [2] . During this era, there were intense discussions about the existence of suppressive or regulatory cell populations, but the inability of researchers to positively identify specific cell types that mediated a suppressive effect shed doubt on the whole concept. Lacking phenotypic markers for suppressor T cells, and without the technological means to isolate, propagate and manipulate suppressor T cells in culture, the therapeutic application of immunoregulatory cell-based products was an untenable proposition [3] .
To move the field forward, it was necessary to specifically identify regulatory cell populations. Critical advances were gradually forthcoming, in particular, studies showing that CD25 [interleukin(IL)-2Ra] could be a useful marker for identifying and purifying CD4 þ T cells with regulatory capacity in rats [4] and detailed experiments in mice that showed CD4 þ
CD25
þ cells specifically control effector T cells responsible for autoimmune pathology [5] . With regard to the identification of natural and induced regulatory T cell (Treg) subsets, the identification of Foxp3 [6] and the methylation status of the FOXP3 gene [7] as reliable markers were critical milestones. Since these discoveries, markers and cultivation methods for other immunoregulatory cell populations, including IL-10-producing Tr1 cells [8] , regulatory macrophages (Mreg) [9,10 & ] and tolerogenic dendritic cells (tolDCs) [11 & ,12,13] , have been defined. Each of these cell types is now being actively investigated as a potential cell-based immunotherapy for use in solid organ transplantation.
Technological advances in cell enrichment and Good Manufacturing Practice (GMP)-compliant production processes are as vital to the pursuit of clinical applications of immunoregulatory as basic scientific knowledge. Indeed, generating immunoregulatory cell products of a sufficiently high quality and on adequate scale to treat patients has represented such a challenge that only a handful of cell products are ready to enter clinical trials. This select group of cell products includes natural Tregs (nTreg), Tr1 cells, alloanergized T cells, M regs, tolDCs, and mesenchymal stromal cells (MSCs) [14 && ,15 && ]. Today, the future of cell-based immunotherapy looks bright: Now, the key question is how clinical trials of cell therapy should be best implemented in the context of solid organ transplantation.
KEY QUESTIONS ABOUT CELL THERAPY IN TRANSPLANT RECIPIENTS
What are the possible advantages of cell-based immunotherapy compared with conventional pharmaceutical agents or mAbs? Current immunosuppressive regimes used in solid organ transplant recipients aim to block the multiply redundant immunological pathways that lead to allograft rejection. Minimally, patients are treated with drugs to inhibit T -cell activation, proliferation and costimulation; as required, this cocktail is often supplemented with B -cell-depleting agents and drugs affecting the innate response. Irrespective of all these treatments, clinical studies continue to show that most organ transplants undergo long-term immunological injury. Moreover, transplanted organs and patients alike are afflicted by the sideeffects of conventional immunosuppressive drugs. Accordingly, there is a growing consensus amongst transplant immunologists that generalized immunosuppression may not bring significant further improvements because every mechanism of 'immunological escape' cannot be blocked. The solution, then, could be the induction of specific immunological regulation towards alloantigen, which is unlikely to be achieved with conventional pharmaceutical agents. This is where cell therapy offers novel solutions. Firstly, unlike conventional immunosuppressants, immunoregulatory cells act when necessary through multiple mechanisms at many pharmacological targets. Secondly, immunoregulatory cells do not function as simple inhibitors: administration of regulatory cells results in a gain-of-function. Immunological regulation is an active, dominant and self-perpetuating state that opposes the effector mechanisms that would otherwise cause transplant rejection. Advocates of cell therapy aspire to instate just such immunological regulation, rather than aiming to constitutively block multiple immunological pathways with an array of suppressive drugs. A principle feature of this approach is that cell therapy would theoretically only need to be applied once, or perhaps a few times, to be effective. Selfsustaining immunological regulation induced by cell therapy has been demonstrated after treatment with Tregs [16, 17] [19, 20] and MSCs [21] in preclinical transplant models and clearly outlives the therapeutic cells themselves. Unfortunately, in all cases, the degree of immunological regulation achieved with cell therapy alone has not resulted in true transplant tolerance, as indefinite graft survival must be supported with some level of concurrent immunosuppressive drug treatment. These issues and experimental results raise a number of key questions: is the goal of cell therapy to eliminate pharmacological immunosuppression, or only to reduce the levels needed?; which regulatory cell populations are most suitable and effective in transplant recipients?; which immunosuppressive drugs are most compatible with effective cell therapy?; will cell therapy be well tolerated?;
KEY POINTS
New treatment strategies are needed for organ transplant recipients to reduce late allograft loss through chronic immunological injury and long-term exposure to general pharmacological immunosuppression.
In an effort to address this problem, cell therapy offers a novel approach to protect organ allografts by adding the function of immune regulation to the immune system of transplant recipients, versus indefinitely inhibiting another important immunological pathway.
Some regulatory cell therapies have recently been developed as advanced therapeutic medicinal products that can now be tested for safety and efficacy in organ transplant recipients, with the aim of reducing long-term exposure to detrimental levels of general immunosuppression.
and, will it be practical and worthwhile to implement the widespread use of cell therapy in organ transplantation? In the following sections of this article, we will begin to address these issues.
PHARMACOLOGY OF IMMUNOREGULATORY CELL PRODUCTS
Much is written about the immunological characteristics of those regulatory cell types that are presently being developed as therapeutics, but it is their pharmacological properties that will ultimately determine their suitability for use as immunosuppressive agents. As with any drug substance, to safely and effectively administer a cell-based immunosuppressive therapy, a treating clinician must understand the pharmacodynamic, pharmacokinetic and toxicological qualities of the cell product. These pharmacological properties necessarily depend on the nature of the active cellular component of a cell product, but are also inextricably linked to the processes by which the cell product is manufactured because the manufacturing process dictates the precise identity (i.e. phenotype) of the active cellular component and its purity. The pharmacodynamics of immunoregulatory cell products, that is to say, the mechanisms by which a particular cell type brings about a desired response and the effective levels that are required to elicit such a response, can be extremely complicated. An important related concept is that of potency, which is a measure of biological activity expressed in terms of the amount of drug required to achieve an effect of given intensity. Pharmacokinetic considerations are likewise complicated in the case of cell-based immunosuppressants because living cells migrate and concentrate in specialized tissue compartments.
As mentioned above, several classes of immunoregulatory cells are currently being developed as immunosuppressive agents, most notably, induced and nTregs, suppressor macrophages and dendritic cells, and MSCs. Despite detailed knowledge about the molecular and cellular functions of these cell types, expert opinion differs on how to best implement such therapies in solid organ transplantation and which cell type will ultimately prove to be the most effective therapy [10 & ]. Because of the central role played by T -cell-mediated regulation in maintenance of allograft tolerance, nTregs and induced Tregs of various types have received most attention [22] . Historically, the greatest challenges in implementing Treg therapy have been precisely specifying the identity of those cells and expanding them without compromising their potency [22] . The nTreg is the only dedicated Treg type and is indispensible for the maintenance of self-tolerance; accordingly, the nTreg is regarded by many immunologists as the most promising cell type for use as a tolerance-inducing therapy [23] . nTregs represent only a small fraction ( 5%) of human peripheral blood CD4 þ T cells, so to obtain sufficient cells for therapeutic application, they must be isolated and expanded ex vivo [24] . Fundamental to any strategy for isolating nTregs is an adequate definition of their cell-surface phenotype: Foxp3 is recognized as the definitive marker of Tregs [25] but, as a nuclear antigen, is unhelpful in purifying live cells; no other single cell-surface marker is sufficient to identify Tregs. Therefore, various enrichment strategies based on isolation of T cells expressing CD4, CD25 [26] [27] [28] and low CD127 [29] [30] [31] Only a fraction of polyclonally expanded nTregs are likely to react to direct donor alloantigen presentation; even fewer polyclonal nTregs would be expected to react in the indirect pathway. With this in mind, researchers are developing a significantly more potent cell product by selecting for donor alloantigen-reactive Tregs [38] . In this case, the trade-off for greater potency is a more complicated and longer manufacturing protocol.
A simpler alternative to purifying Treg populations is to work with impure preparations of induced Treg populations. Roncarolo et al. [39] were the first to describe the immunoregulatory potential of T regulatory type-1 (Tr1) T cells, which do not express Foxp3 and are characterized by constitutive production of IL-10 and not IL-4. This subset arises from conventional T cells after antigenic stimulation in the presence of IL-10, which is achieved under clean room conditions by cultivating recipient peripheral blood mononuclear cells (PBMC) with irradiated, IL-10-treated, monocyte-derived dendritic cells of donor origin [8] . The resultant T -cell population is phenotypically heterogenous but potently suppressive of effector T -cell activation. Although Tr1 cells are ephemeral and represent only a subpopulation of T cells in the final cell product, this mixture has shown therapeutic promise [40] . The T -cell product championed for use in solid organ transplantation by Guinan and Turka is also manufactured without physical enrichment of the active cellular component; instead, polyclonal T cells of recipient origin are directly cocultured with donor antigen-presenting cells (APCs) in the presence of belatacept, a CTLA4-Ig fusion protein [41 & ]. This strong antigenic stimulation in the absence of costimulation leads to a heterogenous population of anergic and induced Tregs [42] . The pharmacodynamic and pharmacokinetic properties of this mixture are not explicitly understood; however, treatment with such 'alloanergized' T -cell preparations led to good outcomes in two phase I clinical trials in haploidentical bone marrow transplantation [43] . That Tr1 cells and alloanergized T cells are generated by exposure to donor alloantigen and act in an alloantigen-specific fashion may partly explain their potency [44] . Thus, induced Treg products may ultimately prove to be simpler, less expensive and equally potent to nTregs.
The existence of anti-inflammatory T -cell-suppressive cells of the myeloid lineage has long been recognized and the ability of such cells to induce tolerance to alloantigens after adoptive transfer has been extensively studied [45] . Although often mooted, progress towards clinical applications of myeloid suppressor cell therapy was limited until recently, when several groups developed GMP-compliant manufacturing processes for suppressive macrophages and tolDC products [10 & ]. Broadly speaking, myeloid suppressor cells are characterized either by an arrested state of immaturity, when they are known as myeloid-derived suppressor cells (MDSCs) or tolDCs, or by a more mature phenotype, reflecting the ability of myeloid APCs to switch into a suppressive mode under certain conditions. Diverse anti-inflammatory treatments prevent dendritic cell maturation in vitro, including generation in the presence of IL-10 (DC-10) [46 & ], rapamycin (Rapa-DC) [19] , or low concentrations of granulocyte-macrophage colony stimulating factor (GM-CSF) (tolDC). Paradoxically, various proinflammatory factors can also drive macrophages and dendritic cells to a suppressive state, including interferon (IFN)-g [47] , prostaglandin E 2 [ [51] . Finally, it is interesting to note that MSCs may induce their suppressive activity through modification of APC differentiation and function [52 & ]. Efforts in our own laboratory to develop a cellbased medicinal product for use in promoting transplant tolerance in renal transplant patients have focussed on human Mreg [9, [53] [54] [55] [56] [57] . The human Mreg reflects a unique state of macrophage differentiation, distinguished from macrophages in other activation states by its mode of derivation, robust phenotype and potent T -cell suppressor function [9] . These cells arise from CD14 þ peripheral blood monocytes during a 7-day culture period during which the cells are exposed to M-CSF, human serum and a final 24-h pulse of IFN-g [58] . Mregs derived in this manner adopt a characteristic morphology and are homogeneously CD14
. Mregs do not stimulate allogeneic T cell proliferation in vitro and, when cocultured with polyclonally stimulated T cells, are potently suppressive of proliferation [9] . The suppressive capacity of Mregs has been attributed to IFN-g-induced indoleamine 2,3-dioxygenase activity, as well as contact-dependent deletion of activated T cells. Preclinical experiments using a heterotopic mouse heart transplant model demonstrate the potential of mouse Mregs to prolong allograft survival: a single intravenous administration of 5 Â 10 6 donor-strain Mregs at 8 days prior to transplantation significantly prolongs allograft survival in unconditioned, nonimmunosuppressed recipients using both the stringent C3H-to-BALB/c and B6-to-BALB/c strain combinations [18 Mreg preparations have now been applied to two living-donor renal transplant recipients with encouraging results [9] . These patients are now more than 4 years posttransplantation and enjoy stable renal function with very low-dose tacrolimus monotherapy as their sole maintenance immunosuppression. Intriguingly, both patients exhibit peripheral blood biomarker profiles that converge upon at least one described gene signature of transplant tolerance [59] .
SAFETY CONSIDERATIONS
Implementing cell-based immunotherapy is a troublesome proposition for many clinicians because its potential risks are unquantified. In general, the risks associated with the intravenous administration of immunoregulatory cell products are broadly similar to those encountered with conventional blood transfusions [60] . The range of possible immunological complications of cell infusion depend upon the nature of the cell product and might include: sensitisation against auto, allo or exogenous antigens; Type I hypersensitivity directed against cellular or noncellular antigens; Type II hypersensitivity resulting in febrile reactions; Type III hypersensitivity leading to immune-complex deposition disease; nonspecific reactions, such as fever resulting from release of pyrogenic cytokines; transfusion-related acute lung injury; and, most seriously, transfusionassociated graft-versus-host disease (in the case of allogeneic cell use). The potential physiological complications of cell infusion include pulmonary embolism of cells or cell aggregates, infusion-related circulatory overload and biochemical disturbances. Infectious diseases communicated by the cell product itself are extremely unlikely, given the rigorous screening of all cell products, but cannot be entirely excluded. As with any immunosuppressive treatment, it is possible that cell-based immunotherapeutics might render patients susceptible to opportunistic infections. Malignant disease after treatment with an immunosuppressive cell product could, in principle, arise either as consequence of transferring neoplastic cells or as consequence of transferred cells promoting growth of autochtonous tumours. In our estimation, the likelihood of those clinical complications listed above is low and the small number of clinical trials using cell-based immunotherapies in solid organ transplantation, graft-versus-host disease (GvHD), rheumatoid arthritis and type-1 diabetes support this view.
STRATEGIES FOR TESTING CELL THERAPIES IN TRANSPLANT RECIPIENTS
There are numerous issues to be confronted when trialling cell therapy in organ transplant recipients for the first time. The first issue is which population of organ transplant recipients to study: are kidney, liver or other organ transplant recipients most suitable? Unfortunately, there is no clear answer to this question. With liver transplantation, rejection as consequence of therapeutic failure can be managed and achieving immunological tolerance is easier in liver recipients than recipients of other organs [61] . Unfortunately, patients awaiting liver transplantation are often very unwell, which complicates the study of their immunological responses. By contrast, potential kidney transplant patients are usually in a stable clinical condition and, in the case of living donation, there is opportunity for carefully planning cell therapy ahead of surgery. This latter point is particularly critical as the high costs of initial testing of cell therapy will limit the number of patients that can be treated. Results from a stable and relatively predictable transplant recipient are expected to allow for a clearer interpretation of trial outcomes.
The second major issue for early studies testing cell therapy is the need to protect recipients by adopting a well tolerated clinical trial protocol. Of course, this immediately forces a compromise: transplant recipients are best protected from acute rejection by standard-of-care immunosuppression; however, conventional immunosuppressive treatment can hinder the function of various immunoregulatory cell types. Furthermore, as the objective of cell therapy in transplantation is to reduce the burden of maintenance immunosuppression, there is an unavoidable conflict between our ability to assess a clinical benefit of cell therapy and the need to ensure the safety of patients. A proposed solution to this dilemma is to test whether cell therapy patients can tolerate some measured level of concurrent immunosuppression tapering without compromising the same allograft survival as patients kept on full maintenance immunosuppression (see Fig. 1 ). Any incremental decrease in long-term use of pharmacological immunosuppression should be deemed a success of cell therapy, because it is of potential benefit to the patient, and should provide motivation for more aggressive immunosuppression minimization in follow-up trials. Thus, clinical success in cell therapy trials would be defined by a well tolerated reduction in life-long pharmacological immunosuppression by promoting immune regulatory function. Importantly, at this early stage in introducing cell therapy into transplantation practice, it is unreasonable to expect patients to develop true immunological tolerance to their allograft. It is our firm opinion that patients given cell therapies in early trials should remain on some level of maintenance immunosuppression to protect against ever-present physiological disturbances of the equilibrium of immune regulation.
A final consideration in the design of cell therapy trials in transplantation is that of intercomparability. With many cell therapy products under development, and the variety of potential immunosuppressive drugs that could be used in conjunction with cell therapy (i.e. calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, antiproliferative agents, corticosteroids and depleting or nondepleting antibodies), how should we ever know which cell product and concurrent immunosuppressive regimen is superior? To avoid this conundrum, and to best serve the worldwide community of transplant recipients, it is imperative for investigators to standardize their clinical trial designs to the greatest possible degree. To achieve this, groups working in cell therapy must pool their knowledge and resources in a coordinated manner through organized networks. With standardized trial protocols and centralized immune monitoring developed through networks, cell products themselves can be largely isolated as the primary variable in trials, allowing for the best possible interpretation of results. A European-led consortium (The ONE Study; http://www.onestudy.org/), forged together with partners from the USA, has this goal in mind and expects to begin comparative cell therapy testing in kidney transplant recipients with the next year [62 & ]. A careful evaluation of these results from The ONE Study will point the way to future applications of cell therapy as a means to minimize (or possibly eliminate) conventional immunosuppression in organ transplantation. If lifelong maintenance immunosuppression can be substantially lowered through any one of the proposed cell therapies, the journey will have been worth the effort.
CONCLUSION
Steady progress has been made towards the implementation of cell-based immunotherapeutics in solid organ transplantation studies. The need for novel approaches to protect allografts from rejection, while at the same time reducing long-term requirements for general immunosuppression, is clearly evident. With this mandate, and the recent advancements in the development of cell therapeutics, the time is right to begin testing whether immunoregulatory therapies will afford better longterm transplant outcomes. A concise review of myeloid suppressor cell therapy regarding the possible cell types that could be used therapeutically. A comparison of the similarities and differences of the possible cell products in this class is provided. 11.
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